BIB

NASDAQ

ProShares Ultra Nasdaq Biotechnology

Sectorn/aIndustryn/aIPOn/a

$82.71-2.94 (-3.43%)

News2/Ratings0

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology IndexÂ®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Latest news

2 items

1160dNEWS
Man in Germany Cured of HIV After Undergoing Stem Cell Transplant, According to Report in Nature Medicine
https://www.dailymail.co.uk/health/article-11772327/Man-CURED-HIV-D-sseldorf-patient-virus-free.html?ito=social-twitter_mailonline https://www.nature.com/articles/s41591-023-02213-x
1590dNEWS
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective as of market open on Monday, Dec. 20. “We are proud to announce our addition to the esteemed Nasdaq Biotechnology Index,” George Goldsmith, CEO and founder of Compass Pathways said. “Our inclusion in this index enables us to reach new audiences as we continue to execute on our clinical development of our investigational COMP360 psilocybin therapy in hopes of addressing the most challenging issues in mental healthcare.” The NBI is designed to track the performance of a set of securities listed on the